Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study

Trial Profile

Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Belinostat (Primary) ; Carfilzomib (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Oct 2014 Planned End Date changed from 1 Apr 2020 to 1 Jan 2018 as reported by ClinicalTrials.gov.
    • 20 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top